Page last updated: 2024-11-08

biguanides and Injuries

biguanides has been researched along with Injuries in 25 studies

Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.
biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.

Injuries: Used with anatomic headings, animals, and sports for wounds and injuries. Excludes cell damage, for which pathology is used.

Research Excerpts

ExcerptRelevanceReference
" Our aim was to assess the clinical efficacy of a propylbetaine-polihexanide (PP) solution versus normal saline (NS) solution in WBP, assessing inflammatory signs and wound size reduction in patients with pressure ulcers (PUs) or vascular leg ulcers."5.22Effect of a wound cleansing solution on wound bed preparation and inflammation in chronic wounds: a single-blind RCT. ( Bellingeri, A; Chiari, P; Falciani, F; Moscatelli, A; Peghetti, A; Russo, A; Tino, G; Traspedini, P, 2016)
"Prevention of wound infections is a challenge in clinical practice."2.87Randomized controlled clinical trial on the antiseptic efficacy of polihexanide 0.04% on acute traumatic wounds. ( Brill, FHH; Csuka, E; Hintzpeter, M; Pahl, S; Payne, B; Simmen, HP, 2018)
"Wounds were assessed for time of dressing change and overall satisfaction of patients and health care providers."2.75Clinical safety and efficacy of a novel thermoreversible polyhexanide-preserved wound covering gel. ( Abels, C; Daigeler, A; Goertz, O; Hirsch, T; Knie, U; Langer, S; May, T; Steinau, HU, 2010)
"Wounds were evenly distributed with respect to etiology and both study groups had a median baseline wound size of 7 cm2."2.71Impact of antimicrobial gauze on bacterial colonies in wounds that require packing. ( Corbett, LQ; Milne, CT; Motta, GJ, 2004)
"The TIME acronym (tissue, infection/inflammation, moisture balance and edge of wound) was first developed more than 10 years ago, by an international group of wound healing experts, to provide a framework for a structured approach to wound bed preparation; a basis for optimising the management of open chronic wounds healing by secondary intention."2.48Extending the TIME concept: what have we learned in the past 10 years?(*). ( Carville, K; Drake, R; Fletcher, J; Leaper, DJ; Schultz, G; Swanson, T, 2012)
"Biofilm in chronic wounds impedes the wound healing process."1.56Synergistic Effect and Antibiofilm Activity of a Skin and Wound Cleanser. ( Bionda, N; D'Arpa, P; McMahon, RE; Poleon, S; Salamone, AB; Salamone, JC, 2020)
"Complex stalled wounds feature an alkaline milieu that favors tissue destruction and microbial growth."1.46Antibacterial activity of polihexanide formulations in a co-culture of HaCaT keratinocytes and Staphylococcus aureus and at different pH levels. ( Andriessen, A; Eberlein, T; Wiegand, C, 2017)
"The use of antibiotics to treat wound infections has decreased due to the increased risk of antibiotic resistance ( Swanson et al, 2014 )."1.46Wound-bed preparation: a vital step in the healing process. ( Barrett, S, 2017)
"Thirty-nine deep partial thickness wounds were created with six wounds assigned to one of six treatment groups: (i) PHMB, (ii) Ringer's solution, (iii) hypochlorous acid/sodium hypochlorite, (iv) sterile water, (v) octenidine dihydrochloride, and (vi) octenilin."1.46Effectiveness of a polyhexanide irrigation solution on methicillin-resistant Staphylococcus aureus biofilms in a porcine wound model. ( Davis, SC; Gil, J; Harding, A; Higa, A; Parajon, F; Solis, M; Valdes, J, 2017)
" This study is designed to assess the effect of antimicrobial-impregnated dressing (AMD) combined with negative-pressure wound therapy (NPWT) on skin graft survival."1.42Antimicrobial-impregnated dressing combined with negative-pressure wound therapy increases split-thickness skin graft engraftment: a simple effective technique. ( Chen, CC; Chew, KY; Kuo, YR; Wu, CC, 2015)
"The treatment of chronic skin wounds through the use of a polyhexanide/propyl betaine-based gel, in combination with a secondary dressing, showed significant improvements, such as a 30% reduction of pain at dressing change, the reduction in the size and characteristics of the wounds and a reduction in the levels of exudate."1.40Evaluation of the effectiveness of a polyhexanide and propyl betaine-based gel in the treatment of chronic wounds. ( Ciprandi, G; Durante, CM; Gallarini, A; Greco, A; Maino, C; Sidoli, O, 2014)
"Standardized in vitro wounds were contaminated with Staphylococcus aureus (MRSA; ATCC 33591) and divided into six groups: no dressing (negative control), methacrylate dressing alone, and combinations with application of 0."1.39Bacterial growth kinetics under a novel flexible methacrylate dressing serving as a drug delivery vehicle for antiseptics. ( Assadian, O; Cutting, KF; Dosch, V; Forstner, C; Kramer, A; Leaper, DJ; Leitgeb, J; Schuster, R, 2013)
"In clinical practice, too many chronic wounds are regarded as being at risk of infection, and therefore many topical antimicrobials - in terms of frequency and duration of use - are applied to wounds."1.37Classification of wounds at risk and their antimicrobial treatment with polihexanide: a practice-oriented expert recommendation. ( Assadian, O; Dissemond, J; Eberlein, T; Gerber, V; Kingsley, A; Kramer, A; Leaper, DJ; Mosti, G; Piatkowski de Grzymala, A; Riepe, G; Risse, A; Romanelli, M; Strohal, R; Traber, J; Vasel-Biergans, A; Wild, T, 2011)
"Chronic wounds are commonly observed in acute and community settings."1.35Topical antimicrobial agents for the treatment of chronic wounds. ( McIntosh, C; Ousey, K, 2009)

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19901 (4.00)18.7374
1990's1 (4.00)18.2507
2000's4 (16.00)29.6817
2010's17 (68.00)24.3611
2020's2 (8.00)2.80

Authors

AuthorsStudies
Jin, J1
Chen, ZL1
Xiang, Y1
Tang, T1
Zhou, H1
Hong, XD1
Fan, H1
Zhang, XD1
Luo, PF1
Ma, B1
Wang, GY1
Xia, ZF1
Salamone, AB1
Salamone, JC1
McMahon, RE1
Poleon, S1
Bionda, N1
D'Arpa, P1
Wiegand, C1
Eberlein, T3
Andriessen, A1
Barrett, S1
Payne, B1
Simmen, HP1
Csuka, E1
Hintzpeter, M1
Pahl, S1
Brill, FHH1
Forstner, C1
Leitgeb, J1
Schuster, R1
Dosch, V1
Kramer, A4
Cutting, KF1
Leaper, DJ3
Assadian, O2
Back, DA1
Scheuermann-Poley, C1
Willy, C1
Durante, CM1
Greco, A1
Sidoli, O1
Maino, C1
Gallarini, A1
Ciprandi, G1
Wu, CC1
Chew, KY1
Chen, CC1
Kuo, YR1
Harding, K1
Bellingeri, A1
Falciani, F1
Traspedini, P1
Moscatelli, A1
Russo, A1
Tino, G1
Chiari, P1
Peghetti, A1
Hurlow, J1
Davis, SC1
Harding, A1
Gil, J1
Parajon, F1
Valdes, J1
Solis, M1
Higa, A1
Valenzuela, AR1
Perucho, NS1
Ousey, K1
McIntosh, C1
Goertz, O1
Abels, C1
Knie, U1
May, T1
Hirsch, T1
Daigeler, A1
Steinau, HU1
Langer, S1
Hammann, A1
Huebner, NO1
Bender, C1
Ekkernkamp, A1
Hartmann, B1
Hinz, P1
Kindel, E1
Koban, I1
Koch, S1
Kohlmann, T1
Lademann, J1
Matthes, R1
Müller, G1
Titze, R1
Weltmann, KD1
Dissemond, J2
Gerber, V2
Riepe, G2
Strohal, R2
Vasel-Biergans, A2
Kingsley, A1
Mosti, G1
Piatkowski de Grzymala, A1
Risse, A1
Romanelli, M1
Traber, J1
Wild, T1
Minnich, KE1
Stolarick, R1
Wilkins, RG1
Chilson, G1
Pritt, SL1
Unverdorben, M1
Schultz, G1
Carville, K1
Fletcher, J1
Swanson, T1
Drake, R1
Motta, GJ1
Milne, CT1
Corbett, LQ1
Wechselberger, F1
Roth, B1
Baltzer, K1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Micro/Nanobubbles (MNBs) and Wound Therapy: A Pilot Study Involving a Novel Oxygen Delivery System for Treatment of Acute and Chronic Wounds[NCT05169814]Early Phase 140 participants (Anticipated)Interventional2021-10-09Recruiting
A Prospective Study of Quality of Life in Patients With Chronic Leg Wound(s) Treated With Prontosan® Wound Irrigation Solution and Prontosan® Wound Gel[NCT03369756]43 participants (Actual)Interventional2018-02-20Terminated (stopped due to Terminated due to prolonged subject recruitment)
Kerlix AMD Gauze Study In A Burn Trauma Unit and Its Effect on Healthcare Associated Infections in Burn Patients[NCT00656708]108 participants (Actual)Interventional2008-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Wound QoL Subscore; Body Dimension

"The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess Body, Psyche and Everyday Life. It can be used in clinical and observational studies and in daily practice.~Subscale Body consists of Items #1 to #5. Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). The average of the subscale can be computed if no more than 1 item of the subscale is missing. The higher values represents more of an impact to the patient for that item." (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)

Interventionscore on a scale (Mean)
Body Subscore change, Baseline / Week 1 to Week 2Body Subscore change, Baseline / Week 1 to Week 3Body Subscore change, Baseline / Week 1 to Week 4Body Subscore change, Baseline / Week 1 to End / Week 5
Prontosan Solution and Gel-0.76-0.93-1.19-1.17

Wound QoL Subscore; Everyday Life Dimension

"The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess Body, Psyche and Everyday Life. It can be used in clinical and observational studies and in daily practice.~Subscale Everyday Life consists of Items #Items #11 to #16. Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). The average of the subscale can be computed if no more than 1 item of the subscale is missing. Generally, the higher values represents more of an impact to the patient for that item." (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)

Interventionscore on a scale (Mean)
Everyday Life Subscore change, Baseline / Week 1 to Week 2Everyday Life Subscore change, Baseline / Week 1 to Week 3Everyday Life Subscore change, Baseline / Week 1 to Week 4Everyday Life Subscore change, Baseline / Week 1 to End / Week 5
Prontosan Solution and Gel-0.58-0.82-1.11-1.00

Wound QoL Subscore; Psyche Dimension

"The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess Body, Psyche and Everyday Life. It can be used in clinical and observational studies and in daily practice.~Subscale Psyche consists of Items #Items #6 to #10. Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). The average of the subscale can be computed if no more than 1 item of the subscale is missing. The higher values represents more of an impact to the patient for that item." (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)

Interventionscore on a scale (Mean)
Psyche Subscore change, Baseline / Week 1 to Week 2Psyche Subscore change, Baseline / Week 1 to Week 3Psyche Subscore change, Baseline / Week 1 to Week 4Psyche Subscore change, Baseline / Week 1 to End / Week 5
Prontosan Solution and Gel-0.77-1.04-1.24-1.26

Wound Size

Change in wound size from Baseline/Week 1 to Final/Week 5. The change in the size of a wound will be evaluated using a disposable ruler to directly measure the overall wound dimensions at each scheduled visit to the study site (Weeks 1 and 5). These measurements will be done before any cleaning of the wound and after cleaning the wound (debridement). (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)

Interventionwound surface area (cm^2) (Mean)
Pre-Debridement Wound Size Change (Baseline/Week 1 to Week 5 / End)Post-Debridement Wound Size Change(Baseline/Week 1 to Final/Week 5)
Prontosan Solution and Gel-6.6-8.2

Wound-QoL Global Score

"The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess Body, Psyche and Everyday Life. These subscales cover items 1 to 16. Item 17 is not part of any of the subscales. The Wound-QoL can be used in clinical and observational studies and in daily practice.~Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). A Total or Global score is the average of at least 13 completed questions, regardless of which questions were not completed. The average of each of the 3 subscales can be computed if no more than 1 item of the subscale is missing. The higher values represents more of an impact to the patient for that item." (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)

Interventionscore on a scale (Mean)
Week 1 / BaselineWeek 2Week 3Week 4Week 5 / End
Prontosan Solution and Gel2.411.741.511.251.30

Reviews

2 reviews available for biguanides and Injuries

ArticleYear
Recommendations on negative pressure wound therapy with instillation and antimicrobial solutions - when, where and how to use: what does the evidence show?
    International wound journal, 2013, Volume: 10 Suppl 1

    Topics: Acetic Acid; Anti-Infective Agents, Local; Biguanides; Cross Infection; Evidence-Based Medicine; Hum

2013
Extending the TIME concept: what have we learned in the past 10 years?(*).
    International wound journal, 2012, Volume: 9 Suppl 2

    Topics: Abbreviations as Topic; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anxiety; Bandages; Bigu

2012

Trials

5 trials available for biguanides and Injuries

ArticleYear
Randomized controlled clinical trial on the antiseptic efficacy of polihexanide 0.04% on acute traumatic wounds.
    The Journal of hospital infection, 2018, Volume: 98, Issue:4

    Topics: Adult; Aged; Anti-Infective Agents, Local; Bacterial Load; Biguanides; Colony Count, Microbial; Doub

2018
Effect of a wound cleansing solution on wound bed preparation and inflammation in chronic wounds: a single-blind RCT.
    Journal of wound care, 2016, Volume: 25, Issue:3

    Topics: Aged; Aged, 80 and over; Bandages; Betaine; Biguanides; Chronic Disease; Female; Humans; Inflammatio

2016
[The effectiveness of a 0.1% polyhexanide gel].
    Revista de enfermeria (Barcelona, Spain), 2008, Volume: 31, Issue:4

    Topics: Administration, Topical; Biguanides; Debridement; Gels; Health Policy; Humans; Pressure Ulcer; Treat

2008
Clinical safety and efficacy of a novel thermoreversible polyhexanide-preserved wound covering gel.
    European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 2010, Volume: 44, Issue:2

    Topics: Adult; Aged; Anti-Infective Agents, Local; Bandages; Biguanides; Female; Gels; Humans; Informed Cons

2010
Impact of antimicrobial gauze on bacterial colonies in wounds that require packing.
    Ostomy/wound management, 2004, Volume: 50, Issue:8

    Topics: Aged; Aged, 80 and over; Bandages; Biguanides; Colony Count, Microbial; Diabetic Foot; Disinfectants

2004

Other Studies

18 other studies available for biguanides and Injuries

ArticleYear
Development of a PHMB hydrogel-modified wound scaffold dressing with antibacterial activity.
    Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society, 2020, Volume: 28, Issue:4

    Topics: Acinetobacter baumannii; Animals; Anti-Infective Agents, Local; Bandages; Biguanides; Disinfectants;

2020
Synergistic Effect and Antibiofilm Activity of a Skin and Wound Cleanser.
    Wounds : a compendium of clinical research and practice, 2020, Volume: 32, Issue:8

    Topics: Biguanides; Biofilms; Detergents; Drug Synergism; Edetic Acid; Glyceryl Ethers; Humans; Methicillin-

2020
Antibacterial activity of polihexanide formulations in a co-culture of HaCaT keratinocytes and Staphylococcus aureus and at different pH levels.
    Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society, 2017, Volume: 25, Issue:3

    Topics: Anti-Bacterial Agents; Bandages; Biguanides; Coculture Techniques; Humans; Hydrogen-Ion Concentratio

2017
Wound-bed preparation: a vital step in the healing process.
    British journal of nursing (Mark Allen Publishing), 2017, Jun-22, Volume: 26, Issue:12 Suppl

    Topics: Administration, Cutaneous; Anti-Bacterial Agents; Anti-Infective Agents, Local; Biguanides; Biofilms

2017
Bacterial growth kinetics under a novel flexible methacrylate dressing serving as a drug delivery vehicle for antiseptics.
    International journal of molecular sciences, 2013, May-21, Volume: 14, Issue:5

    Topics: Animals; Anti-Infective Agents, Local; Bandages; Betaine; Biguanides; Disinfectants; Drug Delivery S

2013
Evaluation of the effectiveness of a polyhexanide and propyl betaine-based gel in the treatment of chronic wounds.
    Minerva chirurgica, 2014, Volume: 69, Issue:5

    Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Betaine; Biguanides; Child; C

2014
Antimicrobial-impregnated dressing combined with negative-pressure wound therapy increases split-thickness skin graft engraftment: a simple effective technique.
    Advances in skin & wound care, 2015, Volume: 28, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bandages; Biguanides; Chronic Disease; Female

2015
Prologue: transformational healing solutions.
    Journal of wound care, 2015, Volume: 24, Issue:4 Suppl

    Topics: Anti-Infective Agents, Local; Bandages; Biguanides; Humans; Negative-Pressure Wound Therapy; Practic

2015
The benefits of using polyhexamethylene biguanide in wound care.
    British journal of community nursing, 2017, Volume: 22 Suppl 3, Issue:Sup3

    Topics: Bandages; Biguanides; Biofilms; Disinfectants; Humans; Wound Infection; Wounds and Injuries

2017
Effectiveness of a polyhexanide irrigation solution on methicillin-resistant Staphylococcus aureus biofilms in a porcine wound model.
    International wound journal, 2017, Volume: 14, Issue:6

    Topics: Animals; Betaine; Biguanides; Biofilms; Disease Models, Animal; Disinfectants; Methicillin-Resistant

2017
[Treatment of ulcus cruris and other chronic wounds. Waiting can cost the foot].
    MMW Fortschritte der Medizin, 2008, Dec-11, Volume: 150, Issue:51-52

    Topics: Biguanides; Chronic Disease; Drug Therapy, Combination; Humans; Leg Ulcer; Silver; Wound Healing; Wo

2008
Topical antimicrobial agents for the treatment of chronic wounds.
    British journal of community nursing, 2009, Volume: 14, Issue:9

    Topics: Administration, Topical; Anti-Bacterial Agents; Bandages; Biguanides; Chronic Disease; Disinfectants

2009
Antiseptic efficacy and tolerance of tissue-tolerable plasma compared with two wound antiseptics on artificially bacterially contaminated eyes from commercially slaughtered pigs.
    Skin pharmacology and physiology, 2010, Volume: 23, Issue:6

    Topics: Animals; Anti-Infective Agents, Local; Antisepsis; Bacteria; Biguanides; Colony Count, Microbial; Co

2010
A practice-oriented recommendation for treatment of critically colonised and locally infected wounds using polihexanide.
    Journal of tissue viability, 2010, Volume: 19, Issue:3

    Topics: Acute Disease; Bacterial Infections; Biguanides; Chronic Disease; Contraindications; Disinfectants;

2010
Classification of wounds at risk and their antimicrobial treatment with polihexanide: a practice-oriented expert recommendation.
    Skin pharmacology and physiology, 2011, Volume: 24, Issue:5

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Local; Biguanides; Humans; Immu

2011
The effect of a wound care solution containing polyhexanide and betaine on bacterial counts: results of an in vitro study .
    Ostomy/wound management, 2012, Volume: 58, Issue:10

    Topics: Betaine; Biguanides; Colony Count, Microbial; Humans; In Vitro Techniques; Wounds and Injuries

2012
[Local management of wounds using the Biotensid wound spray].
    Wiener medizinische Wochenschrift (1946), 1975, Dec-05, Volume: 125, Issue:49

    Topics: Aerosols; Biguanides; Humans; Wound Infection; Wounds and Injuries

1975
[Preventive intraoperative irrigation in wound management with Lavasept. Report of experiences with 1,610 cases].
    Zeitschrift fur Unfallchirurgie und Versicherungsmedizin : offizielles Organ der Schweizerischen Gesellschaft fur Unfallmedizin und Berufskrankheiten = Revue de traumatologie et d'assicurologie : organe officiel de la Societe suisse de ..., 1990, Volume: 83, Issue:4

    Topics: Anti-Infective Agents, Local; Biguanides; Humans; Surgical Wound Infection; Therapeutic Irrigation;

1990